术前放疗对延期两阶段乳房再造的影响
放疗是再造失败显著预测因素,校正吸烟和BMI后OR为17.8(95%CI 5.7-70.6,p<0.01),PRT组失败率30%而非PRT组4%,短期再手术或感染无差异。
要点
- 术前放疗显著增加扩张器/假体再造失败风险(OR 17.8,95%CI 5.7-70.6)。
- PRT组再造失败率30%,非PRT组4%。
- 术前放疗应视为该再造方式的相对禁忌证,需充分告知风险。
核心结论
- 在采用扩张器/假体行延期乳房再造的患者中,术前放疗是再造失败的显著危险因素。
- 术前放疗应被视为该再造方式的相对禁忌证,需谨慎选择患者并告知并发症及可能需额外矫正手术或后期自体乳房再造的风险。
研究设计与样本
- 收集患者描述性数据及手术、住院和并发症数据,采用逻辑回归、Fisher精确检验和多因素分析(R统计软件)。
主要发现
- PRT是再造失败的显著预测因素,校正吸烟和BMI后OR为17.8(95%CI 5.7-70.6;p<0.01)。
- PRT组再造失败15例(30%),非PRT组7例(4%)。
- 两个再造阶段的短期再手术或感染无差异。
临床怎么用
- 对术前接受放疗的延期乳房再造患者,应充分评估扩张器/假体再造的失败风险。
- 术前放疗患者选择扩张器/假体再造时,需告知可能需额外矫正手术或后期自体乳房再造。
- 可将术前放疗视为扩张器/假体延期再造的相对禁忌证,审慎选择患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite a trend towards immediate breast reconstruction in recent years, delayed breast reconstruction using a tissue expander remains a common procedure. Radiotherapy after mastectomy but before reconstruction is a risk factor, although studies examining the effect of this are limited. The aim of this retrospective cohort study is to evaluate the impact of pre-reconstructive radiotherapy (PRT) in patients undergoing breast reconstruction using an expander/implant. MATERIALS AND METHODS: Two hundred twenty-three consecutive patients underwent unilateral mastectomy followed by expander-based reconstruction over a 10-year period (2004-2013). Fifty patients (22%) received radiotherapy before reconstruction (PRT group), and 173 patients (78%) did not (non-PRT group). Descriptive patient data as well as data regarding the operations, hospitalisation and complications were collected. Statistical analyses such as logistic regression, Fisher exact test and multivariate analysis were performed using R-statistics. RESULTS: PRT was a significant predictor of loss of reconstruction, and when adjusted for smoking and body mass index (BMI), it showed an odds ratio (OR) of 17.8 [95% confidence interval (CI): 5.7-70.6; p<0.01] for loss of reconstruction, with 15 (30%) in the PRT group and 7 (4%) in the non-PRT group. We found no difference in short-term reoperations or infections at either stage of reconstruction. CONCLUSION: In patients undergoing delayed breast reconstruction using an expander/implant, radiotherapy is a significant risk factor for loss of reconstruction. It should be considered a relative contraindication for this reconstructive modality, and careful selection and advisement of the patient about the risks of complications and potential need for additional corrective surgery or later autologous breast reconstruction should be discussed.
引用
- Hoejvig JH, Pedersen NJ, Gramkow CS, et al. Delayed two-stage breast reconstruction: The impact of radiotherapy. J Plast Reconstr Aesthet Surg. 2019. PMID: 31350217. doi:10.1016/j.bjps.2019.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。